https://orcid.org/0000-0003-1025-6520
References
- Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–2078.
- Peyrin-Biroulet L, Danese S, Argollo M, et al. Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn’s disease or ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(5):838.e2–846.e2.
- Hsu PS, Lai CL, Hu M, et al. IL-2 enhances gut homing potential of human naive regulatory T cells early in life. J Immunol. 2018;200(12):3970–3980.
- Andrew DP, Berlin C, Honda S, et al. Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation. J Immunol. 1994;153(9):3847–3861.
- Soler D, Chapman T, Yang L-L, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864–875.
- Sun H, Kuk W, Rivera-Nieves J, et al. β7 integrin inhibition can increase intestinal inflammation by impairing homing of CD25hiFoxP3+ regulatory T cells. Cell Mol Gastroenterol Hepatol. 2020;9(3):369–385.
- Wyant T, Yang L, Fedyk E, et al. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. MAbs. 2013;5(6):842–850.
- Goettel JA, Kotlarz D, Emani R, et al. Low-dose interleukin-2 ameliorates colitis in a preclinical humanized mouse model. Cell Mol Gastroenterol Hepatol. 2019;8(2):193–195.